Lung Cancer

A MASTER PROTOCOL OF PHASE 1/2 STUDIES FO NIVOLUMAB IN ADVANCED NSCLC USING NIVOLUMAB AS MAINTENANCE AFTER INDUCTION CHEMOTHERAPY OR AS FIRST-LINE TREATMET ALONG OR IN COMBINATION WITH STANDARD OF CARE THERAPIES

Purpose

In recurrent locally advanced or Stage 4 NSCLC subjects the administration of Nivolumab monotherapy or nivolumab in combination with standard of care (SOC) therapies will provide clinical benefit (ie,progression-free survival [PFS], overall survival [OS], and duration of response [DOR] without unacceptable toxicity).

Who can Join?

Eligible participants may include those with:

  • Advanced or Stage IV Lung Cancer
  • Ability to follow all protocol related visits and treatments
  • Good performance status

What is involved?

  • Routine blood testing as well as study specific testing
  • Physical examinations
  • Evaluation of your progress using CT, MRI or PET scans
  • Possible tumor biopsy
  • Routine questionnaire completion

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL FOR CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Purpose

The purpose of this study is to evaluate the safety and efficacy of MPDL3280A, which is an investigational drung, in combination with carboplatin and nab-paclitaxel for patients who have never had chemotherapy for Stage IV lung cancer.

Who can join?

Eligible participants may include those with:

  • Stage IV lung cancer
  • No treatment for metastatic lung cancer
  • Ability to follow all protocol related visits and treatments

What is involved?

  • Study commitment for up to 26 months
  • Routine blood testing as well as study specific testing
  • Physical examinations
  • Evaluatio of your progress using CT, MRI or PET scans
  • Possible tumor biopsy

A PHASE 3, OPEN-LABEL RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZILUZUMAB COMPARED WITH STANDARD OF CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER

Purpose

The purpose of this study is to look at the effects, good or bad, of atezolizumab on a person as well as lung cancer. Safety and efficacy is being determined as well.

Who can join?

Eligible participants may include those with:

  • Completely resected non-small cell lung cancer
  • Good perfomance status

What is involved?

  • Study commitment for all visits
  • Routiine blood testing as well as study specific testing
  • Physical examinations
  • Evaluations of progress using CT, MRI and PET scans